CEL-SCI : Patient Enrollment In Late-stage Head And Neck Cancer Trial Rises

(RTTNews) - CEL-SCI Corp. (CVM) announced that during the month of June the Company enrolled 19 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). A total of 54 patients were enrolled over the past three months, with 21 enrolled in April, 14 in May, and 19 in June. This marks a 93% increase over the prior three month period when a total of 28 patients were enrolled, with 8 in January, 6 in February, and 14 in March.

Since the beginning of 2014, the Company has enrolled a total of 82 patients. This compares with 10 patients enrolled in the first half of 2013.

So far, a total of 218 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-lable, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

CEL-SCI said it is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.